Journal
BLOOD
Volume 135, Issue 11, Pages 782-785Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2020005041
Keywords
-
Categories
Ask authors/readers for more resources
In this issue of Blood, Liu et al describe the favorable response of adults with relapsed/refractory Epstein-Barr virus (EBV)-associated hemophagocytic lymphohistiocytosis (HLH) to treatment with nivolumab, a programmed cell death-1 (PD-1) inhibitor.1 EBV-HLH presents a challenging clinical conundrum because only a minority of patients will achieve long-standing clinical remission with front-line therapy.(2) To further complicate matters, neither clinical nor pathologic-based criteria have been well established to differentiate which patients are likely to fail upfront HLH therapy with etoposide and dexamethasone.(3,4) Patients with relapsed/refractory disease have a dismal chance of survival because of high rates of disease-related mortality.(2,3)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available